STOCK TITAN

Delcath Systems to Present at Upcoming Virtual Investor Conferences

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Rhea-AI Summary

Delcath Systems (Nasdaq: DCTH) announced its participation in two upcoming virtual investor conferences. The first is the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 17, 2022, at 11:00 AM ET, which will not be webcast. The second event is the 2022 SVB Leerink Global Healthcare Conference on February 18, 2022, at 9:20 AM ET, which will be available via webcast. Delcath focuses on interventional oncology, particularly using its proprietary PHP system for treating liver cancers.

Loading...
Loading translation...
Argus Session date unavailable
-2.09% session move Open Argus
Details

News Market Reaction – DCTH

The recorded move for DCTH in the trading session of this news was -2.09%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences:

  • The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
    • February 17, 2022, at 11:00 AM ET
    • This is a BTIG hosted event and will not be webcast. Please contact your BTIG representative for further information.

  • 2022 SVB Leerink Global Healthcare Conference

To learn more or to schedule a one-on-one meeting with management, please contact your conference representative or james@haydenir.com.

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company’s proprietary percutaneous hepatic perfusion (PHP) system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In the United States, the PHP system is being developed under the tradename HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system), or HEPZATO, for the treatment of metastatic ocular melanoma (mOM), also known as metastatic uveal melanoma (mUM) and is considered a combination drug and device product regulated by the United States Food and Drug Administration (FDA).

In Europe, the PHP system is regulated as a Class IIb medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers of the liver.

Contact:

Delcath Investor Relations

Email: investorrelations@delcath.com

Hayden IR

James Carbonara
(646)-755-7412
james@haydenir.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What conferences will Delcath Systems participate in February 2022?

Delcath Systems will participate in the BTIG Virtual MedTech Conference on February 17 and the 2022 SVB Leerink Global Healthcare Conference on February 18, 2022.

What is the focus of Delcath Systems?

Delcath Systems focuses on interventional oncology, specifically targeting primary and metastatic liver cancers.

What is the PHP system developed by Delcath Systems?

The PHP system is designed for high-dose chemotherapy delivery to the liver while minimizing systemic exposure and side effects.

Keep reading